Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
DRUG
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
8 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.30
vs -0.15
Q4.23
N/A
-0.32
vs -0.10
Q1.24
N/A
-0.10
vs -0.08
Q2.24
+114%
0.04
vs -0.29
Q3.24
N/A
-0.12
vs -0.30
Q4.24
+103%
0.01
vs -0.32
Q1.25
N/A
-0.29
vs -0.10
Q2.25
N/A
-0.53
vs 0.04
Q3.25
N/A
-0.56
vs -0.12
Q4.25
N/A
-0.94
vs 0.01
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-24%
-0.24
vs -0.22
Q2.23
-19%
-0.19
vs -0.24
Q3.23
-23%
-0.23
vs -0.19
Q4.23
-28%
-0.28
vs -0.23
Q1.24
-10%
-0.10
vs -0.28
Q2.24
+4%
0.04
vs -0.10
Q3.24
-14%
-0.14
vs 0.04
Q4.24
+0%
0
vs -0.14
Q1.25
-5%
-0.05
vs 0
Q2.25
-10%
-0.10
vs -0.05
Institutionnal Ownership
QoQ
Q1.23
9
9
vs 9
NA
Q2.23
7
7
vs 9
-22%
Q3.23
5
5
vs 7
-29%
Q4.23
7
7
vs 5
40%
Q1.24
7
7
vs 7
NA
Q2.24
6
6
vs 7
-14%
Q3.24
6
6
vs 6
NA
Q4.24
31
31
vs 6
417%
Q1.25
34
34
vs 31
10%
Q2.25
48
48
vs 34
41%
Relative Strength
DRUG
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Forecast
2026-Revenue
-588%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
BTIG
initialisePrevious: Not converted
2025-09-08
Now: Buy
Cowen & Co.
initialisePrevious: Not converted
2025-05-13
Now: Buy
Cantor Fitzgerald
initialisePrevious: Not converted
2025-01-10
Now: Overweight
H.C. Wainwright
initialisePrevious: Not converted
2025-01-10
Now: Buy
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
NASDAQ
Unprofitable
Unprofitable
4.37 ( 8.60%)
After-hours 54.75$-0.45 (-0.82%)
Relative Strenght
97
Volume Buzz
13%
Earning Acce
No
Dist 52w H.
30%